Cancer Chemotherapy and Pharmacology

, Volume 69, Issue 6, pp 1641–1645 | Cite as

FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study

  • Alberto Zaniboni
  • Enrico Aitini
  • Sandro Barni
  • Daris Ferrari
  • Stefano Cascinu
  • Vincenzo Catalano
  • Giuseppe Valmadre
  • Domenica Ferrara
  • Enzo Veltri
  • Claudio Codignola
  • Roberto Labianca
Original Article

Abstract

Purpose

The purpose of the present study was to evaluate the activity and the tolerability of the FOLFIRI regimen, administered as second-line chemotherapy in patients with locally advanced or metastatic pancreatic cancer after the failure of a gemcitabine-based regimen.

Methods

Patients with locally advanced/metastatic disease who received a first-line chemotherapy (one line only) with gemcitabine ± platinoid (cisplatin, oxaliplatin) and who had measurable disease conform with the RECIST criteria were eligible for the study.

FOLFIRI consists of irinotecan 180 mg/m2 iv on day 1, leucovorin (l-form) 200 mg/m2 iv on day 1 and 2, 5-FU 400 mg/m2 iv bolus on days 1 and 2, and 5-FU 600 mg/m2 iv by ci for 22 h on days 1 and 2, repeated every 2 weeks. The primary end point was the response rate.

Results

Among the 50 enrolled patients, 4 partial responses (PR) (8 %) and 14 stable diseases were observed, for a disease control rate of 18/50 (36 %). Forty-one patients (82 %) have been pretreated with cisplatin/oxaliplatin+gemcitabine as first-line chemotherapy. The median progression-free and overall survivals were 3.2 and 5 months, respectively. The 6-month survival rate was 32 %. Grade 3–4 neutropenia and diarrhea occurred in 10 (20 %) and 6 (12 %) patients, respectively.

Conclusion

The FOLFIRI regimen showed a modest clinical activity in this quite heavily pretreated patients’ population with locally advanced or metastatic pancreatic cancer with a manageable toxicity profile.

Keywords

Pancreatic cancer FOLFIRI Chemotherapy Second-line Irinotecan 

References

  1. 1.
    Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS (2007) National failure to operate on early stage pancreatic cancer. Ann Surg 246:173–180PubMedCrossRefGoogle Scholar
  2. 2.
    Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F; Gruppo Oncologico Italia Meridionale (GOIM), Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente (GISCAD), Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) (2010) Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 28:1645–1651Google Scholar
  3. 3.
    Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A, GERCOR, GISCAD (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509–3516PubMedCrossRefGoogle Scholar
  4. 4.
    Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, National Cancer Institute of Canada Clinical Trials Group (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966Google Scholar
  5. 5.
    Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27:5513–5518PubMedCrossRefGoogle Scholar
  6. 6.
    Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825Google Scholar
  7. 7.
    Ko AH (2011) FOLFIRINOX: a small step or a great leap forward? J Clin Oncol 29:3727–3729PubMedCrossRefGoogle Scholar
  8. 8.
    Boeck S, Heinemann V (2008) The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer. Future Oncol 4:41–50PubMedCrossRefGoogle Scholar
  9. 9.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRefGoogle Scholar
  10. 10.
    Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10PubMedCrossRefGoogle Scholar
  11. 11.
    Kaplan EL, Meier P (1961) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481Google Scholar
  12. 12.
    Custodio A, Puente J, Sastre J, Díaz-Rubio E (2009) Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions. Cancer Treat Rev 35:676–684PubMedCrossRefGoogle Scholar
  13. 13.
    Yi SY, Park YS, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Lee JK, Lee KT, Lim HY, Kang WK (2009) Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Cancer Chemother Pharmacol 63:1141–1145PubMedCrossRefGoogle Scholar
  14. 14.
    Gebbia V, Maiello E, Giuliani F, Borsellino N, Arcara C, Colucci G (2010) Irinotecan plus bolus/infusional 5-fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Clin Oncol 33:461–464PubMedCrossRefGoogle Scholar
  15. 15.
    Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, Lee SS, Seo DW, Lee SK, Kim MH, Han DJ, Kim SC, Lee JL (2009) A randomised phase II study of modified FOLFIRI.3 versus modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 101:1658–1663PubMedCrossRefGoogle Scholar
  16. 16.
    Taïeb J, Lecomte T, Aparicio T, Asnacios A, Mansourbakht T, Artru P, Fallik D, Spano JP, Landi B, Lledo G, Desrame J (2007) FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. Ann Oncol 18:498–503PubMedCrossRefGoogle Scholar
  17. 17.
    Cereda S, Reni M, Rognone A, Ghidini M, Belli C, Longoni S, Fugazza C, Brioschi M, Nicoletti R, Balzano G, Passoni P, Villa E (2010) XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer. Anticancer Res 30:4785–4790PubMedGoogle Scholar
  18. 18.
    Neuzillet C, Hentic O, Rousseau B, Rebours V, Bengrine Lefèvre L, Raymond E, Ruszniewski P, Louvet C, Hammel P (2011) FOLFIRI regimen as second-/third-line chemotherapy in patients with advanced pancreatic adenocarcinoma refractory to gemcitabine and platinum salts: a retrospective series of 70 patients. J Clin Oncol 29 (suppl 4 abstract):272Google Scholar
  19. 19.
    Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, Riess H, Oettle H (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47:1676–1681Google Scholar
  20. 20.
    Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA (2008) Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 113:2046–2052PubMedCrossRefGoogle Scholar
  21. 21.
    Hosein PJ, de Lima Lopes G Jr, Pastorini VH, Gomez C, Macintyre J, Zayas G, Reis I, Montero AJ, Merchan JR, Rocha Lima CM (2012) A phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol Feb 2. (Epub ahead of print)Google Scholar
  22. 22.
    Dimou AT, Syrigos KN, Saif MW (2011) Novel agents in the management of pancreatic adenocarcinoma: phase I studies. Highlights from the “2011 ASCO Gastrointestinal Cancers Symposium”. San Francisco, CA, USA. January 20–22, 2011. JOP 12:114–116Google Scholar
  23. 23.
    National Cancer Institute, National Institutes of Health, US Department of Health and Human Services (2010) COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE), ver 4.03, June 2010. (URL: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf)

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Alberto Zaniboni
    • 1
  • Enrico Aitini
    • 2
  • Sandro Barni
    • 3
  • Daris Ferrari
    • 4
  • Stefano Cascinu
    • 5
  • Vincenzo Catalano
    • 6
  • Giuseppe Valmadre
    • 7
  • Domenica Ferrara
    • 8
  • Enzo Veltri
    • 9
  • Claudio Codignola
    • 10
  • Roberto Labianca
    • 11
  1. 1.Medical Oncology UnitFondazione PoliambulanzaBresciaItaly
  2. 2.Medical Oncology UnitC. Poma HospitalMantuaItaly
  3. 3.Medical Oncology UnitTreviglio-Caravaggio HospitalTreviglioItaly
  4. 4.Medical Oncology UnitS. Paolo HospitalMilanItaly
  5. 5.Medical Oncology UnitUniversità Politecnica delle Marche, Ospedali Riuniti di AnconaAnconaItaly
  6. 6.Medical Oncology UnitOspedali Riuniti Marche Nord, Presidio San SalvatorePesaroItaly
  7. 7.Medical Oncology DHOspedale di SondaloSondaloItaly
  8. 8.Medical Oncology UnitOspedale San CarloPotenzaItaly
  9. 9.Medical Oncology UnitOspedale Don Luigi di LiegroGaetaItaly
  10. 10.Department of SurgeryFondazione PoliambulanzaBresciaItaly
  11. 11.Medical Oncology UnitOspedali RiunitiBergamoItaly

Personalised recommendations